18F-Labeled dihydromethidine: positron emission tomography radiotracer for imaging of reactive oxygen species in intact brain

2020 ◽  
Vol 18 (13) ◽  
pp. 2387-2391 ◽  
Author(s):  
Hiromichi Egami ◽  
Satoshi Nakagawa ◽  
Yuki Katsura ◽  
Masakatsu Kanazawa ◽  
Shingo Nishiyama ◽  
...  

Dihydromethidine (DHM) labeled with 18F at the para position of the benzene ring has been developed as a positron emission tomography (PET) radiotracer for non-invasive imaging of reactive oxygen species (ROS).

2016 ◽  
Vol 52 (27) ◽  
pp. 4888-4890 ◽  
Author(s):  
V. N. Carroll ◽  
C. Truillet ◽  
B. Shen ◽  
R. R. Flavell ◽  
X. Shao ◽  
...  

We report the radiosynthesis of an endogenous redox pair, [11C]ascorbic acid and [11C]dehydroascorbic acid and their application to ROS sensing.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Petra Vahalová ◽  
Kateřina Červinková ◽  
Michal Cifra

AbstractNowadays, modern medicine is looking for new, more gentle, and more efficient diagnostic methods. A pathological state of an organism is often closely connected with increased amount of reactive oxygen species. They can react with biomolecules and subsequent reactions can lead to very low endogenous light emission (biological autoluminescence—BAL). This phenomenon can be potentially used as a non-invasive and low-operational-cost tool for monitoring oxidative stress during diseases. To contribute to the understanding of the parameters affecting BAL, we analyzed the BAL from yeast Saccharomyces cerevisiae as a representative eukaryotic organism. The relationship between the BAL intensity and the amount of reactive oxygen species that originates as a result of the Fenton reaction as well as correlation between spontaneous BAL and selected physical and chemical parameters (pH, oxygen partial pressure, and cell concentration) during cell growth were established. Our results contribute to real-time non-invasive methodologies for monitoring oxidative processes in biomedicine and biotechnology.


2017 ◽  
Vol 8 (1) ◽  
Author(s):  
Martin Thunemann ◽  
Barbara F. Schörg ◽  
Susanne Feil ◽  
Yun Lin ◽  
Jakob Voelkl ◽  
...  

Author(s):  
Ruiqing Ni

Animal models of Alzheimer’s disease amyloidosis that recapitulate cerebral amyloid-beta pathology have been widely used in preclinical research, and have greatly enabled the mechanistic understanding of Alzheimer’s disease and the development of therapeutics. Comprehensive deep phenotyping of the pathophysiological and biochemical features in these animal models are essential. Recent advances in positron emission tomography have allowed the non-invasive visualization of the alterations in the brain of animal models as well as in patients with Alzheimer’s disease, These tools have facilitated our understanding of disease mechanisms, and provided longitudinal monitoring of treatment effect in animal models of Alzheimer’s disease amyloidosis. In this review, we focus on recent positron emission tomography studies of cerebral amyloid-beta accumulation, hypoglucose metabolism, synaptic and neurotransmitter receptor deficits (cholinergic and glutamatergic system), blood-brain barrier impairment and neuroinflammation (microgliosis and astrocytosis) in animal models of Alzheimer’s disease amyloidosis. We further propose the emerging targets and tracers for reflecting the pathophysiological changes, and discuss outstanding challenges in disease animal models and future outlook in on-chip characterization of imaging biomarkers towards clinical translation.


Sign in / Sign up

Export Citation Format

Share Document